HIP 2001
Alternative Names: HIP-2001Latest Information Update: 28 Feb 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atrial fibrillation
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Atrial-fibrillation(Combination therapy, In volunteers) in South Korea
- 08 Mar 2021 Hanmi Pharmaceutical completes a phase I trial in Atrial fibrillation (Combination therapy, In volunteers) in South Korea (unspecified route) (NCT04764201)
- 21 Feb 2021 Hanmi Pharmaceutical completes enrolment in phase I trial in Atrial fibrillation (Combination therapy, In volunteers) in South Korea (unspecified route) (NCT04764201)